Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Amgen 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Amgen 2Q11

Neulasta, Enbrel offset drops in Aranesp, Epogen

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Amgen 2Q11

2Q Revenues: $4.0 billion (+4%)

2Q Earnings: $1.2 billion (-3%)

YTD Revenues: $7.7 billion (+4%)

YTD Earnings: $2.3 billion (-3%)

Comments: Product revenues grew 8% in 2Q11 to $3.9 billion. U.S. sales rose 7% to $2.8 billion while international sales were up 11% to $918 million, with 4% accounted for by exchange rates. Epogen and Aranesp sales both fell in 2Q, offset by growth in Neulasta sales (+18% to $1.0 billion) and Enbrel (+9% to $1.0 billion). The company’s two denosumab products, Prolia and Xgeva, posted sales of $44 million and $73 million, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics